Coronavirus Vaccine: Oxford University and AstraZeneca's experimental COVID-19 vaccine may reap positive results
London : The world is still reeling with the global coronavirus outbreak. This deadly virus which has claimed numerous lives across the globe happens to be highly contagious and has a 14 day incubation period. COVID-19 has infected a large number of people and turned all our world's upside down. This new strain of coronavirus has no cure or vaccine. This is why the best minds across the globe are working hard day and night to find a way out and save lives. India currently has 9,36,181 confirmed coronavirus cases out of which3,19,840 are active and 5,92,031 have been cured or discharged. The current COVID-19 death toll in India is at 24,309.
Currently, there are over 100 coronavirus vaccines being developed across the world to combat this global COVID-19 pandemic. Numerous companies and scientists are in the middle of clinical trials for a vaccine that can protect us from coronavirus. In the current scenario, a vaccine might be our only hope and way out of this global health crisis.
Oxford University and AstraZeneca are working in collaboration for a potential vaccine. Their vaccine is currently in phase III clinical trials on a large scale. The results of phase I have not been published by the company yet. The reports would help us all understand if the potential vaccine can induce an immune response or not and also if it's safe for human use or not. AstraZeneca and the University of Oxford's vaccine are one of the leading vaccines under development for our battle against coronavirus. It is expected that the results of phase I trials will be published soon in the Lancet Medical Journal. As reported by Business Standard, the developers of the vaccine said that, this month they were encouraged by the immune response that they have seen in the trials so far and were expecting to publish the phase I data by the end of July.
This potential COVID-19 vaccine is being developed by the University of Oxford and has been licensed to AstraZeneca and the company has signed agreements with the governments around the world to supply the vaccine if it gets cleared for usage.